大分割全乳放疗同步瘤床加量的急性不良反应:HYPOSIB随机对照试验结果
HYPOSIB是一项随机对照非劣效性试验,纳入保乳术后乳腺癌患者2310例,1:1随机接受16次大分割全乳放疗同步瘤床加量(HYPOSIB)或标准方案。分析集2264例显示,HYPOSIB组最重放射性皮炎发生率更低(2级25.3% vs 38.6%;3级2.3% vs 3.1%),但潮热更常见(2级29.7% vs 26.0%;3级8.6% vs 6.8%),仅3.3%潮热判定为放疗相关;疼痛和乳房不适在标准治疗中更频繁。
要点
- HYPOSIB方案16次大分割全乳放疗同步瘤床加量,最重放射性皮炎发生率显著低于标准方案。
- HYPOSIB组放射性皮炎发生更早但消退更快,疼痛和乳房不适在标准治疗中更频繁。
- HYPOSIB组潮热更常见,但仅3.3%判定为放疗相关。
核心结论
- HYPOSIB方案16次大分割全乳放疗同步瘤床加量导致最重放射性皮炎临床相关降低。
- 两种治疗在放射性皮炎、疼痛和乳房不适的发生时间上存在差异,HYPOSIB组不良事件发生和消退更早。
研究设计与样本
- HYPOSIB为随机对照非劣效性试验,2015年6月至2019年1月纳入2310例保乳术后乳腺癌患者,1:1随机分组。
- 分析集包括2264例接受放疗的知情同意患者,HYPOSIB组接受全乳40 Gy/16次同步瘤床加量48 Gy。
- 标准组由研究者选择:常规分割放疗同步加量、序贯分割放疗或序贯大分割放疗。
- 本稿件聚焦预设的选定急性不良事件(放射性皮炎、疼痛、乳房压迫感即乳房不适),按CTCAE v4.0评估至治疗后3个月。
主要发现
- HYPOSIB组最重放射性皮炎发生率更低:2级25.3% vs 38.6%,3级2.3% vs 3.1%。
- HYPOSIB组放射性皮炎发生更早但消退更快。
- HYPOSIB组最重潮热更常见:2级29.7% vs 26.0%,3级8.6% vs 6.8%;仅3.3%潮热判定为放疗相关。
- 疼痛和乳房不适在标准治疗中及HYPOSIB后较晚时间点更频繁,与放射性皮炎的时间趋势一致。
关键数值与推荐
- HYPOSIB方案:全乳40 Gy/16次,瘤床同步加量48 Gy。
- 标准方案由研究者选择:常规分割放疗同步加量、序贯分割放疗或序贯大分割放疗。
- 急性不良事件按CTCAE v4.0评估至治疗后3个月。
临床怎么用
- 对于保乳术后需全乳放疗加瘤床加量的患者,可考虑16次大分割同步瘤床加量方案以降低最重放射性皮炎。
- 采用HYPOSIB方案时应告知患者放射性皮炎可能发生更早但消退更快,潮热可能更常见但多为非放疗相关。
- 标准方案治疗中及治疗后较晚时间点需关注疼痛和乳房不适的发生。
局限性
- 本稿件仅报告预设的选定急性不良事件,随访至治疗后3个月,未报告长期结局。
- 标准组治疗方案由研究者选择,包含多种分割模式,可能引入异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Moderate hypofractionation is standard of care for adjuvant whole-breast irradiation after breast-conserving surgery. Although boost irradiation has traditionally been administered sequentially after whole-breast irradiation, a growing amount of data suggests that delivery of a simultaneous integrated boost (SIB) may be equally effective and tolerable. METHODS AND MATERIALS: HYPOSIB is a randomized controlled noninferiority trial enrolling patients with breast cancer after breast-conserving surgery. Patients were randomized 1:1 to HYPOSIB (40 Gy in 16 fractions to the breast with SIB of 48 Gy to the tumor bed) or to the standard arm (investigator's choice: conventionally fractionated radiation therapy with SIB or sequentially fractionated radiation therapy or sequential hypofractionation). The focus of this manuscript is the secondary endpoint of selected prespecified acute adverse events (radiation dermatitis, pain, feeling of pressure in the breast-further termed breast discomfort) according to Common Terminology Criteria for Adverse Events version 4.0 up to 3 months after treatment. RESULTS: From June 2015 to January 2019, 2310 patients were enrolled. The analysis set included 2264 consenting patients that received radiation therapy. HYPOSIB resulted in fewer cases with worst grade of radiation dermatitis (grade 2: 25.3% vs 38.6%; grade 3: 2.3% vs 3.1). Radiation dermatitis occurred earlier during HYPOSIB but resolved more rapidly. There were more worst grade hot flashes during the HYPOSIB (grade 2: 29.7% vs 26.0%; grade 3: 8.6% vs 6.8%). Only 3.3% of hot flashes were judged as radiation therapy-related. Pain and breast discomfort were more frequent during the standard treatment and at later time points after HYPOSIB, mirroring the temporal trends for radiation dermatitis. CONCLUSIONS: HYPOSIB in 16 fractions led to a clinically relevant reduction in worst grade radiation dermatitis. There were temporal differences between treatments in the occurrence of radiation dermatitis, pain, and breast discomfort with adverse events occurring and resolving earlier with HYPOSIB.
引用
- Krug D, Vonthein R, Schreiber A, et al. Acute Adverse Events of Hypofractionated Whole-Breast Radiation Therapy With a Simultaneous Integrated Boost-Results From the Randomized Controlled HYPOSIB-Trial (ARO 2013-05). Int J Radiat Oncol Biol Phys. 2026. PMID: 42537852. doi:10.1016/j.ijrobp.2026.07.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。